RecruitingNot ApplicableNCT02811653
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
155 participants
Start Date
Dec 16, 2015
Study Type
INTERVENTIONAL
Conditions
Summary
In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.
Eligibility
Min Age: 40 YearsMax Age: 85 Years
Inclusion Criteria11
- Patients
- Age between 40 and 85
- French mother tongue
- Consulting at the Amiens Memory Resource and Research Centre (CMRR) for:
- MCI, according to Albert et al.'s criteria (Albert et al., 2011)
- Mild dementia (MMSE>20) due to AD, according to McKhann's criteria (McKhann et al., 2011).
- Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005).
- Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011).
- Social security coverage
- Healthy controls
- Healthy age and gender matched volunteers will be recruited into the study from the general population.
Exclusion Criteria24
- Reading or writing difficulties related to a learning disorder or illiteracy.
- A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure):
- NYHA stage IV dyspnoea.
- respiratory impairment requiring oxygen therapy.
- liver impairment.
- kidney failure, progressing neoplastic disease, or past or present alcohol abuse.
- Past or present neurological disorders other than those having prompted consultation in the Memory Clinic:
- stroke.
- meningitis or encephalitis.
- severe head injury.
- sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments).
- epilepsy (requiring ongoing treatment),
- psychiatric disorders (other than treated depression).
- treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state.
- Impossibility to perform a neuropsychological evaluation or brain MRI.
- Withdrawal from the study at any time, if desired.
- Pregnancy
- Contra-indication to MRI:
- nerve stimulators
- cochlear implants
- ferromagnetic foreign bodies close to nervous structures in the eye or brain
- cerebral shunts
- dental appliances
- Legal guardianship or incarceration.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEBrain MRI
OTHERneuropsychological evaluation
BIOLOGICALBlood
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02811653
Related Trials
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
NCT072213443 locations
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787289 locations
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
NCT067813331 location
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
NCT07011745140 locations
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
NCT057092101 location